ALBERTA PRECISION LABORATORIES
Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	17 June 2024
TO:	All Zones – Physicians, Nurses, Pharmacists, and Managers
FROM:	Clinical Biochemistry, Alberta Precision Laboratories (APL)
RE:	**Realignment of *Infliximab Levels* with the World Health Organization Standard**

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective **June 17, 2024,** the Immundiagnostik (IDK) *Infliximab Level* enzyme linked immunosorbent assay (ELISA) calibration will realign with the National Institute for Biological Standards and Controls (NIBSC) Infliximab World Health Organization (WHO) standard.

Background

- Over the past year, Alberta Precision Laboratories has been working closely with Affinity Diagnostics to correct calibration drift especially for Infliximab levels above the therapeutic range.

How this will impact you

- The new lot of calibrators are expected to produce a negative proportional bias (i.e., on average shift Infliximab levels down by 25%). The shift will be more noticeable at Infliximab levels above 10ug/mL.
- An *Infliximab Level* comment will append in the report to alert physicians.

Action Required

- Known inflammatory bowel disease patients undergoing *Infliximab Level* therapeutic drug monitoring will require re-baselining.

Questions/Concerns

- Dr. Kareena Schnabl, Clinical Biochemist, UAH Special Chemistry Lab: 780 407-3186; Kareena.schnabl@aplabs.ca

Approved by

- Dr. Allison Venner, Section Chief Clinical Biochemistry, South Sector, APL
- Dr. Michael Mengel, Medical Director, North Sector, APL
- Dr. Dylan Pillai, Medical Director, South Sector, APL

Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.